Eribulin Mesylate Injection
Product Images NDC 40033-364

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 40033-364). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kindos Pharmaceuticals Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Package (Eribulin Mesylate Injection 1 mg/2 mL Carton)

Principal Display Package (Eribulin Mesylate Injection 1 mg/2 mL Carton)
This text contains information about Eribulin Mesylate Injection, including dosage, composition, storage instructions, and cautions related to its cytotoxic nature. It provides details such as the concentration of the drug per volume, temperature storage requirements, and the need for pH adjustment. The product is intended for intravenous use, and each single-dose vial should be discarded if unused. Additional details may be found in the prescribing information. The drug is manufactured by a company located in China.*
FDA Label Image

Figure 1 (Eribulin K32 Figure1 V2)

Figure 1 (Eribulin K32 Figure1 V2)
This text provides information on a research study involving eribulin mesylate injection with a total of 508 participants. The data includes a timeline spanning up to 36 months and shows the number of patients at risk at different time points. It also mentions a control group with 254 participants.*
FDA Label Image

Figure 2 (Eribulin K32 Figure2 V2)

FDA Label Image

Structural Formula (Eribulin K32 Structure V2)

FDA Label Image

Principal Display Package (Eribulin Mesylate Injection 1 mg/2 mL Vial Label)

Principal Display Package (Eribulin Mesylate Injection 1 mg/2 mL Vial Label)
This description provides information on a sterile solution, Eribulin Mesylate injection intended for intravenous use. It contains 1 mg/2 ml (0.5 mg/ml) and should not be frozen or refrigerated. The storage recommendations are 15°C - 30°C (50°F - 86°F). The product is a cytotoxic agent and comes in a single-dose vial. Specific dosage instructions are available in the accompanying prescribing information.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.